HCW Biologics
Yahoo Finance • 4 days ago
HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
MIRAMAR, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to exten... Full story
Yahoo Finance • last year
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
MIRAMAR, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen hea... Full story
Yahoo Finance • last year
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
Showed HCW9218 clinical safety and tumor response endpoints for 15 patients with heavily pretreated advanced solid tumors Results in ovarian cancer patients outpace other indications, with 66% stable disease MIRAMAR, Fla., Nov. 08, 2023... Full story
Yahoo Finance • last year
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen hea... Full story
Yahoo Finance • last year
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
MIRAMAR, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen he... Full story
Yahoo Finance • 2 years ago
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
MIRAMAR, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen hea... Full story
Yahoo Finance • 2 years ago
HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights
MIRAMAR, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen heal... Full story
Yahoo Finance • 2 years ago
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
Provides funding for buildout of new headquarters and manufacturing facility Capital requirements now funded into 2025 MIRAMAR, Fla., April 27, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCW... Full story
Yahoo Finance • 2 years ago
HCW Biologics Poster Presentation at AACR Annual Meeting 2023
Presentation of data for the mechanism underlying HCW9218 against solid tumors HCW9218 is the clinical-stage, lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., April 13, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Compa... Full story
Yahoo Finance • 2 years ago
HCW Biologics Enters CRADA with National Cancer Institute
MIRAMAR, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen hea... Full story
Yahoo Finance • 2 years ago
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting
Presentation includes data on safety and dosage escalation and immune system reaction to HCW9218 No incidence of mucosal bleeding resulting from the HCW9218 TGF-β trap HCW9218 is one of the lead product candidates of HCW Biologics Inc.... Full story
Yahoo Finance • 2 years ago
HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights
MIRAMAR, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen hea... Full story
Yahoo Finance • 2 years ago
HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights
MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen hea... Full story
Yahoo Finance • 3 years ago
HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights
MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disr... Full story
Yahoo Finance • 3 years ago
HCW Biologics’ CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022
Preclinical data for lead investigational drug, HCW9218, in treatment of therapy-induced senescence in cancer Debut of preclinical data related to age-associated diseases MIRAMAR, Fla., April 19, 2022 (GLOBE NEWSWIRE) -- HCW Biologics... Full story
Yahoo Finance • 3 years ago
HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021
$56 Million IPO Completed in July 2021 Expected to Fund Operating Expenses through 2023 FDA Clearance for Initial Clinical Trials in Two Difficult-to-Treat Cancer Indications Publication of Three Pivotal Scientific Papers in Peer-Reviewe... Full story
